<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2508">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128513</url>
  </required_header>
  <id_info>
    <org_study_id>Y (2021) 38</org_study_id>
    <nct_id>NCT05128513</nct_id>
  </id_info>
  <brief_title>Delipid Extracorporeal Lipoprotein Filter From Plasma (DELP) for Acute Hemorrhagic Stroke</brief_title>
  <official_title>Delipid Extracorporeal Lipoprotein Filter From Plasma (DELP) for Acute Hemorrhagic Stroke: a Prospective, Random, Open-label, Blind-endpoint, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve&#xD;
      neurological function and life ability of AIS patients and approved for the treatment of AIS&#xD;
      by China Food and Drug Administration (CFDA). A recent study imply that the neuroprotective&#xD;
      effect of DELP involved multiple neuroprotective mechanism such as anti-inflammation, free&#xD;
      radical scavenging, and decreasing MMP-9. Based on the multiple mechanisms, the investigator&#xD;
      argues that DELP may exert neuroprotective effect on acute cerebral hemorrhage (ACH). In this&#xD;
      context, the prospective, random, open-label, blind-endpoint, multi-centre study is designed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 2</measure>
    <time_frame>Day 90</time_frame>
    <description>the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 1</measure>
    <time_frame>Day 90</time_frame>
    <description>the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distribution of modified Rankin Score</measure>
    <time_frame>Day 90</time_frame>
    <description>the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in National Institute of Health stroke scale (NIHSS)</measure>
    <time_frame>24 hours and 2 weeks</time_frame>
    <description>the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the occurence of stroke or other vascular events</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes in cerebral hematoma volume</measure>
    <time_frame>24 hours</time_frame>
    <description>the hematoma volume was formulated by brain CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the severe adverse events</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the occurence of death due to any cause</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>DELP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) is a non-pharmacological therapy for acute stroke, which is approved by China Food and Drug Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DELP</intervention_name>
    <description>The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.</description>
    <arm_group_label>DELP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-80;&#xD;
&#xD;
          -  Spontaneous cerebral hemorrhage;&#xD;
&#xD;
          -  Deep supratentorial intracerebral hemorrhage (basal ganglia) with hematoma volume&#xD;
             5-40ml, or supratentorial lobar hemorrhages with hematoma volume 5-30ml;&#xD;
&#xD;
          -  NIHSS: 6-20;&#xD;
&#xD;
          -  Time from onset to DELP: 6-48 hours;&#xD;
&#xD;
          -  Premorbid mRS 0 or 1;&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary cerebral hemorrhage (secondary to trauma, tumor, vascular malformation,&#xD;
             hemorrhage transformation of ischemic stroke, etc.);&#xD;
&#xD;
          -  Comatose patients on admission (GCS score 3-8 on the Glasgow Coma Scale);&#xD;
&#xD;
          -  Patients with intracerebral hemorrhage ruptured into the ventricle, which should be&#xD;
             treated by surgery;&#xD;
&#xD;
          -  Planed surgery;&#xD;
&#xD;
          -  Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of&#xD;
             upper limit of normal value), increase in serum creatinine (more than 1.5 times of&#xD;
             upper limit of normal value) or requiring dialysis;&#xD;
&#xD;
          -  Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure&#xD;
             over 110 mmHg), or hypotension (systolic blood pressure below 90mmHg or diastolic&#xD;
             blood pressure below 60 mmHg);&#xD;
&#xD;
          -  Previous allergy to heparin or calcium;&#xD;
&#xD;
          -  Life expectancy is less than 6 months due to comorbidity&#xD;
&#xD;
          -  Infected at the venipuncture site&#xD;
&#xD;
          -  hypoproteinemia;&#xD;
&#xD;
          -  Unsuitable for this clinical studies assessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui-Sheng Chen</last_name>
    <phone>+8624897511</phone>
    <email>chszh@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Head of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

